Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELCADE Subcutaneous vs Intravenous in Previously Treated Multiple Myeloma
NCT00722566Phase 3Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Jul 2008
- Primary completion
- Aug 2010
- Modality
- Small Molecules, Modified Peptides
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of bortezomib in multiple myeloma (MM) (2 arms), sponsored by Millennium Pharmaceuticals. Primary endpoint: Overall Response Rate at 12 weeks. Started Jul 2008; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00722566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00722566.